{"entity":{"id":"nct06926075","kind":"trial","name":"Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","aka":[],"tldr":"A phase 1/2 trial of A novel hGIIA-Vimentin Inhibitor in prostate cancer, ovarian cancer, glioma & glioblastoma, pancreatic ductal adenocarcinoma and skin cancer, run by Filamon LTD, now recruiting.","summary":"Early Phase Study of KESONOTIDE™in Participants With Solid Tumours is a phase 1/2 interventional study registered as NCT06926075 by Filamon LTD, with 80 participants planned, started 2025-11-07 and due to reach its primary completion in 2027-10-26. Interventions recorded: A novel hGIIA-Vimentin Inhibitor and Dose expansion.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06926075","url":"https://clinicaltrials.gov/study/NCT06926075"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","ovarian","glioblastoma","pancreatic","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06926075","phase":"1/2","setting":"An Adaptive Phase I/II Study of KESONOTIDE™, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours","sponsor":"Filamon LTD","enrolled":80,"outcomes":[]},"route":"/trials/nct06926075/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}]}}